Trial Profile

Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ravulizumab (Primary)
Indications Haemolytic uraemic syndrome; Myasthenia gravis; Neuromyelitis optica; Paroxysmal nocturnal haemoglobinuria
Focus Adverse reactions
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

07 Jan 2025 Planned End Date changed from 29 Nov 2033 to 24 Oct 2034.
07 Jan 2025 Planned primary completion date changed from 29 Nov 2033 to 24 Oct 2034.
28 Aug 2024 Planned number of patients changed from 300 to 75.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com